Rocket Pharmaceuticals (RCKT) Reports Preliminary Data from Phase 1/2 Trial of RP-L201 for Leukocyte Adhesion Deficiency-I
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Rocket Pharmaceuticals (RCKT) Prices 3.82M Share Common Offering at $22.25/Sh
December 11, 2019 5:59 AM ESTRocket Pharmaceuticals, Inc. (NASDAQ:... More
Rocket Pharmaceuticals (RCKT) Announces Proposed Common Share Offering
December 10, 2019 4:02 PM ESTRocket... More
Rocket Pharmaceuticals (RCKT) PT Raised to $33 at Chardan Capital Markets
December 9, 2019 8:02 AM ESTChardan Capital Markets analyst Geulah Liveshits raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $33.00 (from $30.00) while maintaining a Buy rating.
The analyst commented, "On 8 November, Rocket Pharmaceuticals presented preliminary data on ex vivo lentiviral gene therapy RP-L102 for Fanconi anemia (FA), manufactured with commercial-grade "Process B", demonstrating (1) 2-3x higher product vector copy numbers (VCNs) vs. Process A product, and (2) signals of engraftment in patients at 6 months. The data, presented in a poster at the American Society of Hematology (ASH) 2019 Annual... More
Rocket Pharmaceuticals (RCKT) Highlights Promising Preliminary Results from Phase 1 Trial of Commercial-Grade RP-L102 'Process B' for Fanconi Anemia
December 9, 2019 6:27 AM ESTRocket Pharmaceuticals, Inc. (NASDAQ: RCKT) today announces encouraging preliminary results from its Phase 1 trial of commercial-grade RP-L102 Process B for Fanconi Anemia (FA) at the 61st American Society of Hematology (ASH) Annual Meeting. The data are highlighted in a poster presentation by Agnieszka Czechowicz M.D., Ph.D., Assistant Professor of Pediatrics,... More
Rocket Pharmaceuticals (RCKT) PT Raised to $41 at Baird, Added to Fresh Pick List
December 6, 2019 8:16 AM ESTBaird analyst Madhu Kumar raised the price target on Rocket Pharmaceuticals (NASDAQ: RCKT) to $41.00 (from $30.00) while maintaining a Outperform rating.
Adds to Fresh Pick list.The analyst comments "Prior to Rocket Pharmaceuticals' (RCKT) data release at the American Society... More
